البلد: الاتحاد الأوروبي
اللغة: الإنجليزية
المصدر: EMA (European Medicines Agency)
crisantaspase
Jazz Pharmaceuticals Ireland Limited
L01XX02
crisantaspase
Antineoplastic agents
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Authorised
2023-09-15
23 B. PACKAGE LEAFLET 24 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ENRYLAZE 10 MG/0.5 ML SOLUTION FOR INJECTION/INFUSION recombinant crisantaspase This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Enrylaze is and what it is used for 2. What you need to know before you are given Enrylaze 3. How Enrylaze is given 4. Possible side effects 5. How Enrylaze is stored 6. Contents of the pack and other information 1. WHAT ENRYLAZE IS AND WHAT IT IS USED FOR Enrylaze contains the active substance recombinant crisantaspase. It is a medicine used alongside other medicines to treat acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Enrylaze can be given to patients aged 1 months of age or older. Enrylaze contains a protein made in the laboratory by recombinant DNA technology. This protein works by decreasing the amount of a protein called asparagine. This protein is needed by the ALL and LBL cancer cells to survive. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ENRYLAZE _ _ YOU SHOULD NOT RECEIVE ENRYLAZE • if you have a severe allergic reaction to Enrylaze. • if you have an allergic reaction to any of the other ingredients of this medicine (listed in section 6). • if you are currently experiencing severe pancreatitis (inflammation of the pancreas). • i اقرأ الوثيقة كاملة
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Enrylaze 10 mg/0.5 mL solution for injection/infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 0.5 mL solution of 10 mg of recombinant crisantaspase* The amino acid sequence is identical to native L-asparaginase from _Erwinia chrysanthemi_ (also known as crisantaspase). An _in-vitro_ activity assay demonstrated that 1 mg of recombinant crisantaspase approximates 1 000 U of native crisantaspase, consistent with the _in-vivo_ comparisons from clinical trials. Serum asparaginase activity (SAA) exposures (C max , concentration at 48h & 72h and AUC) have been shown to be comparable for 25 mg/m 2 recombinant crisantaspase and 25 000 U/m 2 native crisantaspase, when administered intravenously or intramuscularly in healthy subjects. *recombinant _Erwinia chrysanthemi_ L-asparaginase produced in _Pseudomonas fluorescens_ by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion. Clear to opalescent, colourless to slightly yellow solution with a pH of 7.0 ± 0.5 and an osmolality: 290–350 mOsmol/Kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to _E. coli_ -derived asparaginase. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Enrylaze should be prescribed and administered by physicians and healthcare personnel experienced in the use of antineoplastic products. Appropriate resuscitation equipment and other agents necessary اقرأ الوثيقة كاملة